NCT01457118 - An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

August 31, 2017

Study Completion Date

November 30, 2017

Conditions

Malignant Solid Tumor

Interventions

DRUG

NKTR-102 145 mg/m2

A 90 minute IV infusion of 145 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.

DRUG

NKTR-102 120 mg/m2

A 90 minute IV infusion of 120 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.

DRUG

NKTR-102 95 mg/m2

A 90 minute IV infusion of 95 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.

DRUG

NKTR-102 50 mg/m2

A 90 minute IV infusion of 50 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.

Trial Locations (7)

Investigator Site - Liege, Liège

Investigator Site - Cleveland, Cleveland

Investigator Site - Minneapolis, Minneapolis

Investigator Site - Los Angeles, Los Angeles

Investigator Site - Whittier, Whittier

Investigator Site - San Francisco, San Francisco

Investigator Site - Bruxelles, Brussels